Making Sense of CLL Therapy

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a typical median age at diagnosis around 70 years. Management of CLL has changed substantially from the historical chemotherapy and chemoimmunotherapy era to a targeted-therapy model driven by disease biology, prognostic markers, patient fitness, comorbidities, treatment tolerance, and patient preference.

This CME/CE activity reviews the biology of CLL and explains how genetic and molecular risk factors influence frontline treatment selection. Participants will examine key prognostic markers, including 13q deletion, 11q deletion, TP53 mutation, 17p deletion, and IGHV mutation status, with emphasis on why high-risk patients historically had poor outcomes with chemoimmunotherapy and why modern targeted agents have improved progression-free survival across clinically important subgroups.

The activity focuses on first-line therapy options, including covalent Bruton tyrosine kinase (BTK) inhibitors such as acalabrutinib and zanubrutinib, BCL2 inhibition with venetoclax, anti-CD20 monoclonal antibody combinations, fixed-duration regimens, continuous therapy, and emerging minimal residual disease (MRD)-guided strategies. Faculty discussion highlights pivotal trial evidence, therapeutic tradeoffs, and adverse-event considerations, including atrial fibrillation, hypertension, neutropenia, infections, tumor lysis syndrome, treatment discontinuation, and clinic-visit burden.

By the end of the program, learners should be better prepared to personalize first-line CLL therapy by integrating disease risk, patient age and fitness, cardiac history, concomitant medications such as anticoagulants, risk of tumor lysis syndrome, caregiver support, cost, resistance considerations, and patient goals regarding continuous versus time-limited treatment.

Educational Objectives

After completing this activity, learners will be able to:

• Describe core CLL biology and the prognostic relevance of common genetic and molecular abnormalities, including deletion 13q, deletion 11q, TP53 mutation, 17p deletion, and IGHV mutation status.
• Compare current first-line treatment strategies for CLL, including BTK inhibitors, BCL2 inhibitor-based regimens, anti-CD20 combinations, fixed-duration therapy, continuous therapy, and MRD-guided approaches.
• Apply patient-, disease-, and treatment-specific factors to select an appropriate first-line CLL therapy and anticipate clinically relevant adverse events.

Who Should Do This Course?

• Hematologists and medical oncologists managing patients with CLL
• Oncology fellows and clinicians seeking a practical update on frontline CLL treatment selection.
• Advanced practice providers involved in CLL care, including nurse practitioners and physician associates/assistants.
• Oncology nurses, pharmacists, and allied health professionals supporting treatment education, monitoring, and adverse-event management.
• Primary care clinicians who coordinate care for older adults with hematologic malignancies.

Did You Know?

• CLL is described as the most common leukemia in adults, and the median age of diagnosis is approximately 70 years in the United States.
• TP53 aberrations may occur as TP53 gene mutation or 17p deletion and are especially important because they influence treatment selection and response expectations.
• Second-generation BTK inhibitors were developed to improve selectivity and reduce off-target adverse events compared with first-generation ibrutinib.
• Venetoclax-based regimens introduced a fixed-duration option for frontline CLL therapy but require careful tumor lysis syndrome monitoring during ramp-up.
• MRD-guided treatment is an emerging approach that may help personalize the duration of therapy in selected CLL regimens.

The estimated time to complete this activity is 30mins.